Catalyst
Slingshot members are tracking this event:
Amgen (AMGN) Phase 3 study with KYPROLIS in combination with DARZALEX treating relapsed or refractory multiple myeloma enrolls first patient in Q2 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AMGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 30, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Kyprolis, Darzalex, Relapsed Multiple Myeloma
